Last updated 2026-07-26
- Acquired by NLS Pharmaceutics, Oct 2025
- Raised $20M Follow-on PO, Feb 2021
- Raised $2.5M Follow-on PO, Sep 2025
Total raised
$29.4M
Last: Undisclosed Round 2026-04
Stage
Public
Founded
2025
Headcount
11
HQ
Kloten, Switzerland
Sector
Health Tech & Life Sciences
About
NewCelX is an innovative biopharmaceutical company focused on developing transformative stem-cell-derived therapies for Type 1 Diabetes and neurodegenerative diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments. NewCelX was formed on October 30, 2025, through the merger of NLS Pharmaceutics Ltd. from Zurich, Switzerland, and Kadimastem Ltd. from Nes Ziona, Israel.
Funding history · 5 rounds · $29.4M total
5 events/rounds · $29.4M Total Funding: $29.4M in Public Equity
Sep 2025
Jul 2024
Mar 2024
Apr 2022
Feb 2021
Headcount over time
11 employees (2026-09) · 1 point
Offices
Kloten, Switzerland · HQ / main office
Q&A
- What is NewCelX's primary focus?
- NewCelX is a biopharmaceutical company focused on developing transformative stem-cell-derived therapies for Type 1 Diabetes and neurodegenerative diseases.
- When was NewCelX formed and how?
- NewCelX was formed on October 30, 2025, through the merger of NLS Pharmaceutics Ltd. from Zurich, Switzerland, and Kadimastem Ltd. from Nes Ziona, Israel.
- What is the current employee count for NewCelX?
- NewCelX currently has 11-50 employees.
- What is the total amount of funding NewCelX has raised to date?
- NewCelX has raised a total of $45,350,000 USD.
- Who are some of the key executives at NewCelX?
- Key executives at NewCelX include Ronen Twito (Executive Chairman & Chief Executive Officer), Alexander C. Zwyer (Chief Business Officer & Executive Director), and Omri Hagai (Chief Financial Officer).
- Has NewCelX been involved in any public offerings?
- Yes, NewCelX has had several public offerings, with the most recent one in September 2025.
Team · 8
Michel Revel
Founder · Director & Chief Scientific Officer
Ronen Twito
Executive Chairman & Chief Executive Officer
Alex Zwyer
Director & Chief Business Officer
Olivier Samuel
Independent Director
Liora Oren
Independent Director
Eran Iohan
Independent Director
Tammy Galili
Director
Arik Hasson
EVP R&D
Sectors & technology
Primary sector
Health Tech & Life Sciences
Technologies
Target customers
Business model
B2B
Highlights
Patents
Tags
pharma-companiesstem-cellsdiabetesdegenerative-diseasesbioprocessneurologycell-therapyregenerative-medicinebiological-therapyamyotrophic-lateral-sclerosis-alsbiotechnologymedical-researchhealthcare
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | newcelx.com/ |
|---|---|
| linkedin.com/company/1515403 |
Identifiers & details
| Legal name | NewcelX Ltd. |
|---|---|
| Founded | 2025-10 |
| Employees (exact) | 11 |
Acquisitions & public offerings
Acquired by NLS Pharmaceutics 2025-10
Radar intelligence
Web history (Wayback)
| Domain | newcelx.com |
|---|
Certificate / subdomain footprint
| Subdomains | 3 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 514192558 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה ציבורית |
| Incorporated | 2008-10-06 |
| Purpose | לעסוק בכל עיסוק חוקי למעט בסוגי עסקים שפורטו בתקנון |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2011 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | ספיר פנחס 7 נס ציונה |